What US Diagnostics Companies Get Wrong About Canadian Market Entry

Most US diagnostics companies approach Canada expecting that clinical evidence and regulatory approval will translate into adoption. This assumption is reasonable in markets with centralized payer systems, but Canada's fragmented provincial structure creates a fundamentally different dynamic.

Canada is not one market. Ontario, Québec, British Columbia, and Alberta each have distinct funding models, evidence requirements, and implementation pathways. A strategy that works in Ontario may not apply in Québec, and vice versa.

Strong science is necessary but not sufficient. Diagnostics stall when the evidence package does not align with what provincial decision-makers actually evaluate — which often differs from what regulatory bodies require.

Approval without adoption is common. A product can clear Health Canada review and still fail operationally if laboratory workflows, turnaround expectations, or institutional procurement processes are not addressed.

The result is often delayed entry, misallocated budget, and commercial plans built on assumptions that don't hold across provinces. Companies that invest in understanding these dynamics early tend to make better sequencing decisions and avoid costly mid-course corrections.